APA (7th ed.) Citation

J, B., AA, L., S, J., SA, W., L, P., DY, T., . . . JE, R. (2018). Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British journal of cancer, 119(6), 707. https://doi.org/10.1038/s41416-018-0261-0

Chicago Style (17th ed.) Citation

J, Bellmunt, et al. "Everolimus and Pazopanib (E/P) Benefit Genomically Selected Patients with Metastatic Urothelial Carcinoma." British Journal of Cancer 119, no. 6 (2018): 707. https://doi.org/10.1038/s41416-018-0261-0.

MLA (9th ed.) Citation

J, Bellmunt, et al. "Everolimus and Pazopanib (E/P) Benefit Genomically Selected Patients with Metastatic Urothelial Carcinoma." British Journal of Cancer, vol. 119, no. 6, 2018, p. 707, https://doi.org/10.1038/s41416-018-0261-0.